相关实验视频
Updated: Jun 28, 2025

09:48
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
360
转移性乳腺癌:在常规瘤治疗中延长生命
Rudolf Weide1,2, Stefan Feiten2, Christina Waßmann3
1Praxis für Haematologie und Onkologie Koblenz, 56068 Koblenz, Germany.
Cancers
|April 13, 2024
概括
转移性乳腺癌 (MBC) 患者的整体存活率在27年的日常护理中显著改善. 这项研究证实了在临床试验中看到的进展转化为现实世界患者的结果.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 流行病学 流行病学
背景情况:
- 转移性乳腺癌 (MBC) 的整体存活率 (OS) 改善是在临床试验中记录的.
- 这些试验进展对常规临床护理的转化效益仍在争论中.
研究的目的:
- 追溯分析在日常护理中未经选择的转移性乳腺癌 (MBC) 患者的整体生存 (OS) 趋势.
- 确定临床试验生存率的改善是否反映在现实环境中.
主要方法:
- 对1995年至2022年间诊断的1610名未经选择的女性MBC患者的回顾性分析.
- 来自五个瘤组实践和一所大学门诊所收集的数据.
- 基于初始MBC诊断日期的不同时间队列的OS趋势的评估.
主要成果:
- 平均 OS 持续从 31.6 个月 (1995-2000) 延长到 48.4 个月 (2018-2022) (p=0.003).
- 确定了时间队列,转移状态,年龄,激素/HER2状态,一般状况,转移局部和器官参与等显著的生存依赖.
- 多变量分析突出了受体状态,一般状况,转移部位和从初始诊断到MBC诊断的时间作为关键生存预测因素.
结论:
- 转移性乳腺癌患者的整体存活率在过去27年中在常规护理中持续显著改善.
- 这些发现表明,临床试验的进步正在有效地转化为改善现实世界患者群体的结果.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

